Table 1: Demographic,
pre-operative and surgical characteristics of the study population.
|
Variable |
N=85 (%) mean±SD |
|
Males |
52 (61.2%) |
|
Age |
65.5±9.35 |
|
ECOG PS 0 1 2 |
49 (57.6%) 31 (36.5%) 5 (5.9%) |
|
Modified CCI 0 1 2 3 4 |
25 (29.4%) 30 (35.3%) 20 (23.5%) 9 (10.6%) 1 (1.2%) |
|
Comorbidities Hypertension CAD COPD Other solid tumor Diabetes Mellitus Vascular disease |
29 (34.1%) 7 (8.2%) 27 (31.7%) 5 (5.8%) 12 (14.1%) 3 (3.5%) |
|
Clinical stage IIIA IIIB |
63 (74.1%) 22 (25.9%) |
|
Pre-operative FEV1% |
85.4±18.2 |
|
Pre-operative DLCO% |
68±15.1 |
|
Invasive mediastinal staging EBUS/EUS VM |
70 (82.4%) 15 (17.6%) |
|
CDDP other |
48 (55.8%) 38 (44.2%) |
|
ADC SCC other |
48 (56.5%) 30 (35.3%) 7 (8.2%) |
|
RECIST response CR PR SD |
6 (7.1%) 51 (60%) 28 (32.9%) |
|
Surgical procedure Lobectomy/Bilobectomy Pneumonectomy Sublobar resection Sleeve lobectomy |
53 (62.3%) 14 (16.5%) 4 (4.7%) 14 (16.5%) |
|
Site of tumor Upper/Middle Lobe Lower lobe |
56 (65.9%) 29 (34.1%) |
|
Single station involvement More than one station involved |
42 (49.4%) 43 (50.6%) |
SD: Standard Deviation; ECOG PS: Eastern Cooperative Oncology Group
Performance Status; CCI: Charlson Comorbidity Index; CAD: Coronary Artery
Disease; COPD: Chronic Obstructive Pulmonary Disease; FEV1%: Forced Expiratory
Volume in 1 Second, DLCO%: Diffusing Capacity of the Lung for Carbon Monoxide,
Hb: Haemoglobin; EBUS/EUS: Endobronchial or Esophageal Ultrasound; VM:
Videomediastinoscopy; CDDP: Cisplatin Based Chemotherapy; ADC: Adenocarcinoma;
SCC: Squamous Cell Carcinoma; RECIST: Response Evaluation Criteria in Solid
Tumors; CR: Complete Response; PR: Partial Response; SD: Stable Disease.